Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study

Next Previous
X
Search
Trial Profile

A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omidenepag isopropyl (Primary) ; Timolol
  • Indications Exfoliation syndrome; Ocular hypertension; Open-angle glaucoma; Pigmentary glaucoma
  • Focus Adverse reactions; Registrational
  • Acronyms RENGE
  • Sponsors Santen Pharmaceutical

    • Most Recent Events

    • 01 Nov 2021 Primary endpoint (Change and percent change from baseline in mean diurnal IOP and mean IOP at each scheduled timepoint) has been met as per results published in the Japanese Journal of Ophthalmology
    • 01 Nov 2021 Results published in the Japanese Journal of Ophthalmology
    • 16 Nov 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top